Drugs / KT-413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05233033 | Jun 2022 → Jul 2023 | diffuse large B-cell lymphoma | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05233033 ↗ |
| Route | Intravenous | “administered intravenously” NCT05233033 ↗ |